{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"relapsed CD30 expressing lymphoma","name":"RELY-30","nct_id":"NCT02917083","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rely-30-nct02917083. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RELY-30","arms":[{"description":"Each patient will receive one infusion of CAR modified T cells. Unless post autologous transplant, patients will receive lymphodepleting chemotherapy as three daily doses of cyclophosphamide (Cy: 500mg/m2/day) together with fludarabine (Flu:30mg/m2/day) from 48 hours to 2 weeks before T cell infusion. Clofarabine (20 mg/m2/day) may be substituted for fludarabine.","label":"CD30.CAR T Cells","type":"EXPERIMENTAL"}],"collaborators":["The Methodist Hospital Research Institute"],"completion_date":{"date":"2040-02","type":"ESTIMATED"},"conditions":["Hodgkin's Lymphoma","Non-Hodgkin Lymphoma"],"enrollment":{"count":60,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"CAR T Cells","otherNames":["CD30.CAR T Cells"],"type":"GENETIC"}],"last_update":"2026-10-02","lead_sponsor":"Baylor College of Medicine","official_title":"Phase I Study of Relapsed CD30 Expressing Lymphoma Treated With CD30 CAR T Cells (RELY-30)","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Patients with Dose-Limiting Toxicities (DLT)","timeFrame":"6 weeks"}],"references":[{"citation":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 Nov 10;38(32):3794-3804. doi: 10.1200/JCO.20.01342. Epub 2020 Jul 23.","pmid":"32701411","type":"DERIVED"}],"start_date":{"date":"2017-05-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)","url":"https://clinicaltrials.gov/study/NCT02917083"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rely-30-nct02917083"}